IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.221
AS - Asia 5.880
EU - Europa 4.628
SA - Sud America 1.663
Continente sconosciuto - Info sul continente non disponibili 613
AF - Africa 285
OC - Oceania 9
AN - Antartide 1
Totale 33.300
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.704
SG - Singapore 2.587
IT - Italia 1.560
BR - Brasile 1.293
CN - Cina 994
HK - Hong Kong 759
SE - Svezia 739
RU - Federazione Russa 617
FR - Francia 439
VN - Vietnam 375
GB - Regno Unito 320
DE - Germania 273
IN - India 228
CA - Canada 224
BD - Bangladesh 220
FI - Finlandia 127
BE - Belgio 112
AR - Argentina 107
TR - Turchia 107
ID - Indonesia 83
MX - Messico 80
CO - Colombia 78
IQ - Iraq 78
ZA - Sudafrica 78
UA - Ucraina 68
EC - Ecuador 59
JP - Giappone 59
CI - Costa d'Avorio 58
VE - Venezuela 54
PK - Pakistan 53
PL - Polonia 50
ES - Italia 48
CZ - Repubblica Ceca 40
NL - Olanda 34
SA - Arabia Saudita 34
AT - Austria 30
CR - Costa Rica 29
IL - Israele 29
UZ - Uzbekistan 29
MY - Malesia 28
AE - Emirati Arabi Uniti 25
MA - Marocco 25
PR - Porto Rico 25
LT - Lituania 23
HN - Honduras 22
IE - Irlanda 22
SV - El Salvador 21
GT - Guatemala 20
KE - Kenya 20
PH - Filippine 20
CL - Cile 19
ET - Etiopia 19
TT - Trinidad e Tobago 19
JM - Giamaica 18
JO - Giordania 18
NP - Nepal 18
CW - ???statistics.table.value.countryCode.CW??? 16
NI - Nicaragua 16
BG - Bulgaria 15
BO - Bolivia 15
DZ - Algeria 15
IR - Iran 15
TN - Tunisia 14
CH - Svizzera 13
EG - Egitto 13
PY - Paraguay 13
PT - Portogallo 11
RS - Serbia 11
UY - Uruguay 11
KR - Corea 10
SY - Repubblica araba siriana 10
HR - Croazia 9
KZ - Kazakistan 9
PE - Perù 9
QA - Qatar 9
TH - Thailandia 9
AZ - Azerbaigian 8
BH - Bahrain 8
DO - Repubblica Dominicana 8
GP - Guadalupe 8
KW - Kuwait 8
RO - Romania 8
KG - Kirghizistan 7
LY - Libia 7
PA - Panama 7
AL - Albania 6
DK - Danimarca 6
HU - Ungheria 6
LB - Libano 6
PS - Palestinian Territory 6
SC - Seychelles 6
AU - Australia 5
BB - Barbados 5
BY - Bielorussia 5
LV - Lettonia 5
NO - Norvegia 5
SR - Suriname 5
AO - Angola 4
GE - Georgia 4
GR - Grecia 4
Totale 32.608
Salva come PNG Salva come JPEG
Città #
Ashburn 2.298
Fairfield 2.052
Chandler 1.759
Singapore 1.446
San Jose 1.241
Woodbridge 1.029
Seattle 929
Cambridge 906
Houston 860
Hong Kong 752
Wilmington 656
Milan 621
Nyköping 564
Council Bluffs 417
Ann Arbor 395
Beijing 394
Dallas 341
Los Angeles 303
New York 292
Lawrence 245
Lauterbourg 234
Roxbury 229
Rome 225
Santa Clara 179
Des Moines 149
Columbus 127
The Dalles 122
Ho Chi Minh City 114
Brooklyn 113
São Paulo 111
Brussels 110
Paris 109
San Diego 104
Chicago 93
Inglewood 91
Dearborn 90
London 88
Munich 87
Hanoi 86
Boardman 83
Atlanta 81
Jacksonville 81
Helsinki 78
Moscow 74
San Francisco 74
Phoenix 68
Denver 67
Figino 59
Abidjan 58
Bari 58
Montreal 57
Pune 57
Tokyo 56
Buffalo 54
Frankfurt am Main 54
Orem 49
Jakarta 45
Turin 45
Washington 43
Rio de Janeiro 42
Warsaw 42
Nanjing 40
Toronto 35
Chennai 33
Johannesburg 32
North Bergen 30
Baghdad 29
Mexico City 29
Turku 28
Bologna 27
Edinburgh 27
San Mateo 27
Belo Horizonte 26
Brasília 26
Brno 26
Istanbul 26
Tashkent 26
Ankara 25
Falkenstein 25
Falls Church 25
Boston 24
Naples 24
Princeton 24
Stockholm 24
Da Nang 23
Guangzhou 23
Porto Alegre 23
Campinas 22
Dong Ket 22
Dublin 21
Guayaquil 21
Poplar 21
Shanghai 21
Vienna 21
Amsterdam 20
Charlotte 20
Jinan 20
Ruvo Di Puglia 20
Bogotá 19
Manchester 19
Totale 22.260
Salva come PNG Salva come JPEG
Nome #
Molecularly targeted endocrine therapies for breast cancer 1.028
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 408
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 271
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 271
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 264
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 264
Angiogenesis in adenosquamous cancer of pancreas 238
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 216
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 196
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 193
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 193
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 184
Targeting angiogenesis in biliary tract cancers: An open option 182
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 182
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 181
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 181
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 179
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 175
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 174
Bone metastases in biliary cancers: A multicenter retrospective survey 174
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 173
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 172
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 172
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 171
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 171
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 169
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 168
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia. 167
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 167
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 167
Oncosuppressor methylation: A possible key role in colon metastatic progression 167
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 166
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 165
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 165
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 165
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 163
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 163
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 163
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 158
Challenges and opportunities of MicroRNAs in lymphomas 158
Antineoplastic drug-induced bradyarrhythmias 157
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 156
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 156
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 156
Target therapies in pancreatic carcinoma 155
Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis 154
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 154
Synthetic lethality to overcome cancer drug resistance 154
Molecular classifications of gastric cancers: Novel insights and possible future applications 154
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 154
Adjuvant therapy in colon cancer 153
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 152
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 152
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 152
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 149
Combined modality treatments in pancreatic cancer 149
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 149
Immunotherapeutic approaches for hepatocellular carcinoma 148
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery 148
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 148
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 148
Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine 148
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 147
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 147
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 147
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 146
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 146
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 146
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 146
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 146
Management of patients with end-stage renal disease undergoing chemotherapy: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN) 145
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 144
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 144
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 144
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer 144
Hydroxy-propil-β-cyclodextrin inclusion complexes of two biphenylnicotinamide derivatives: Formulation and anti-proliferative activity evaluation in pancreatic cancer cell models 144
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 143
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 143
New molecular targets in bone metastases 143
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 142
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 142
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 142
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 141
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 141
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 140
p53 as the main traffic controller of the cell signaling network 140
Actors on the scene: Immune cells in the myeloma niche 140
Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey 140
Unique case of giant adult paratesticular spindle cell rhabdomyosarcoma 139
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 137
Current status of targeted therapies in advanced gastric cancer 137
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 137
Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and metaanalysis 137
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 136
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 135
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 135
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials 135
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 135
Immunotherapy for colorectal cancer: where are we heading? 133
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 133
Totale 17.192
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.064
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 149.064
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.711 0 0 0 0 159 149 110 133 142 111 224 683
2022/20233.687 399 514 291 360 316 413 111 474 541 25 203 40
2023/20241.168 84 216 80 101 123 322 19 66 9 28 10 110
2024/20254.546 95 82 359 207 153 513 381 418 162 222 734 1.220
2025/202610.765 1.489 407 596 826 1.278 530 1.132 306 1.050 776 907 1.468
2026/20273.084 504 597 658 1.222 103 0 0 0 0 0 0 0
Totale 33.300